Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Viloxazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 7/20 | 0.97 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.97 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | HTR2B | P41595 | 2/20 | 0.97 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.97 |
| ▸ | HTR1A | P08908 | 1/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.78 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.60 |
| ▸ | HRH1 | P35367 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.60 |
| ▸ | HTR3A | P46098 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.56 |
| ▸ | MLNR | O43193 | 1/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Viloxazine SCHEMBL25394508 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL30439261 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL29362568 | 1.00 | SLC6A4 (0.97) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL30589854 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL29359040 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL34168 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL2524730 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (S)-Viloxazine SCHEMBL31126415 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| (R)-Viloxazine SCHEMBL2524727 | 0.99 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B | |
| Viloxazine SCHEMBL1651391 | 0.96 | SLC6A4 (0.95) | SLC6A4SLC6A2SLC6A3HTR2AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 250 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026044401-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VILOXAZINE | APOTEX INC (CA) | 2026-03-05 | — | — | WO | claimed |
| US-20250367208-A1 | FORMULATIONS OF VILOXAZINE | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-12-04 | — | — | US | claimed |
| US-20250228859-A1 | FORMULATIONS OF VILOXAZINE | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-07-17 | — | — | US | claimed |
| US-20250222004-A1 | FORMULATIONS OF VILOXAZINE | SUPERNUS PHARMACEUTICALS, INC. (US) | 2025-07-10 | — | — | US | claimed |
| CN-119792220-A | Venloxazine hydrochloride sustained-release tablet and preparation method thereof | 北京万全德众医药生物技术有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119707868-A | Willoxazine hydrochloride product impurity and synthetic method and application thereof | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119707645-A | Synthesis method of viloxazine hydrochloride product impurities | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119707851-A | Willoxazine hydrochloride product impurity and synthetic method and application thereof | 西安远大科创医药科技有限公司 | 2025-03-28 | — | — | CN | claimed |
| CN-119269664-A | Method for detecting genotoxic impurities in viloxazine hydrochloride | 苏州恩华生物医药科技有限公司 | 2025-01-07 | — | — | CN | claimed |
| US-12178838-B2 | Synthetic neuromodulatory peptides | LACTOCORE, INC. (US) | 2024-12-31 | — | — | US | claimed |
| WO-2011130194-A2 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2011-10-20 | — | — | WO | claimed |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | SUPERNUS PHARMACEUTICALS INC. (US) | 2011-10-13 | — | — | US | claimed |
| US-7973043-B2 | Administering an antidepressant in combination with an antipsychotic drug, for therapy of major depressive disorder categorized as non-treatment resistant and non-psychotic | MIGALY PETER | 2011-07-05 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| US-20060150989-A1 | Method of diagnosing, treating and educating individuals with and/or about depression | MIGALY PETER | 2006-07-13 | — | — | US | claimed |
| EP-0923370-B1 | ACETYL CHOLINE ESTERASE INHIBITORS FOR TREATING AND DIAGNOSING SLEEP DISORDERED BREATHING | CURAPATH AB (SE) | 2005-11-16 | — | — | EP | claimed |
| EP-1551393-A2 | COMBINATION THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE, AND VAROUS MEDICAL AND PSYCHIATRIC CONDITIONS | Migaly, Peter (US) | 2005-07-13 | — | — | EP | claimed |
| US-20040204401-A1 | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions | MIGALY PETER (US) | 2004-10-14 | — | — | US | claimed |
| WO-2004010932-A2 | COMBINATION THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE, AND VAROUS MEDICAL AND PSYCHIATRIC CONDITIONS | MIGALY PETER (US) | 2004-02-05 | — | — | WO | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250367208-A1 | FORMULATIONS OF VILOXAZINE | HTR5A, CYP3A5, HTR2A | SLC6A2 77/4885SLC6A4 44/4885SLC6A3 246/4885 |
| US-20250228859-A1 | FORMULATIONS OF VILOXAZINE | HTR5A, CYP3A5, HTR2A | SLC6A2 77/4885SLC6A4 44/4885SLC6A3 246/4885 |
| US-20250222004-A1 | FORMULATIONS OF VILOXAZINE | HTR5A, CYP3A5, HTR2A | SLC6A2 77/4885SLC6A4 44/4885SLC6A3 246/4885 |
| US-20110251198-A1 | METHODS FOR PRODUCING VILOXAZINE SALTS AND NOVEL POLYMORPHS THEREOF | CYP3A5, VIL1, CYP3A4 | SLC6A2 629/4885SLC6A4 229/4885SLC6A3 1062/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.